Clinical Trial

Pembrolizumab in Treating Participants With Leukoplakia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II pilot trial studies how well pembrolizumab works in treating leukoplakia. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2018-07-18; most recent amendment 2026-07-07.
Status change: Not Yet Recruiting → Recruiting 2019-06-26
Trial Details
NCT Number NCT03603223
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: Merck Sharp & Dohme LLC
Conditions Erythroleukoplakia, Leukoplakia, Verrucous Oral Leukoplakia
Enrollment 26 participants
Start Date 2019-05-03
Primary Completion 2027-08-01 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-09